Sartorius announced on Mar. 17 the launch of its Eveo Cell Therapy Platform, an integrated system designed to improve the production and quality control of autologous cell therapies. The company said this new platform aims to address structural manufacturing bottlenecks that limit the scalability and patient access to treatments such as CAR-T therapies.
The introduction of the modular Eveo platform is intended to strengthen Sartorius’s position in the advanced therapies market. According to Sartorius, current centralised facilities for autologous cell therapy require significant investment, staff recruitment, training, and lengthy build-up phases. The company noted that about 60% of regulatory disruptions in cell therapies are due to manufacturing and process-related issues.
The Eveo system integrates steps including cell selection, activation, gene modification, expansion, wash, concentration, and final formulation into a closed system. Sartorius said its compact design allows for implementation in existing facilities with current staff and supports both centralised and decentralised manufacturing models. This could allow operation in lower-classification environments compared to traditional systems.
Sartorius collaborated with ElevateBio and other partners during pilot testing of the platform. The company reported that a single operator can process eight patient batches at once using Eveo in the same cleanroom space typically needed for two batches. With a seven-day manufacturing time per batch over 50 weeks per year, this could result in more than 350 doses annually—nearly four times more than current methods. Financial modelling by Sartorius suggests that manufacturing costs could be reduced by around 90%, while also easing challenges related to quality control.
“Cell therapies are redefining medical possibilities,” said René Fáber, member of the Executive Board at Sartorius. “Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on. By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients.”
Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026 with first deliveries expected in 2027. ElevateBio will be among the first partners granted access to use the new platform.
